This elevated P/S multiple suggests that investors are valuing the company as a high-growth software-enabled MedTech entity rather than a traditional hardware manufacturer. The lack of a positive P/E or EV/EBITDA multiple warrants caution, as the current valuation is highly sensitive to the company's ability to maintain its 36% revenue growth trajectory while simultaneously narrowing its operating losses.

The persistent negative ROIC suggests that the capital deployed into sales infrastructure and R&D has not yet reached an inflection point where it generates returns exceeding the cost of capital. Investors should monitor whether the company can improve its asset turnover, which currently sits at a low 0.14, as this is a primary driver of the current capital inefficiency.

The extended CCC indicates that the company's working capital management is currently inefficient compared to more mature medical device peers. While the high gross margins provide a buffer, the inability to rapidly turn over inventory may exacerbate liquidity pressures if the company fails to scale its sales volume in line with its current inventory procurement levels.

While a current ratio of 10.30 appears superficially strong, the underlying cash burn rate suggests that this liquidity position is deteriorating rapidly. The company's reliance on cash to fund operations, combined with the lack of positive free cash flow, indicates that the current liquidity buffer may be insufficient to support long-term operations without future capital raises.